PCC Public Advisory

 

System Maintenance Advisory: MAO E-Notification System

Please be advised that the MAO E-Notification System will undergo scheduled maintenance to implement system enhancements from 01 April to 06 April 2026. During this period, the system will be temporarily unavailable.

The last day for electronic submissions through the MAO E-Notification System will be on 31 March 2026 (5:00 PM).

If there are submissions due during the scheduled maintenance period, all concerned parties are advised to ensure the early submission of the necessary documents prior to the maintenance dates.

The enhanced MAO E-Notification System will resume normal operations on Tuesday, 07 April 2026.

For any questions or concerns, please contact the Mergers and Acquisitions Office via email at mergers@phcc.gov.ph or by telephone at +632 8771 9722 local 252.

Please be guided accordingly.

 

 

 

Advisory: LMS Rebranding to PCC eCLASS

In line with its rebranding efforts, PCC's Learning Management System (LMS), previously known as iCLP: Online Learning Hub on Competition Law and Policy, will now be called PCC eCLASS: Enhanced Competition Learning Activities Spaces.

Correspondingly, the platform’s domain name will be changed from iclp.phcc.gov.ph to eclass.phcc.gov.ph.

Please be advised that the LMS will be temporarily unavailable from March 27, 2026 (5:00 PM) to March 31, 2026 (11:59 PM) to facilitate this transition.

Beginning April 1, 2026, users may access PCC’s online courses through the new domain.

 

 

 

PCC Advisory: Trunkline Service Interruption

 

Close this Modal

/ Commission Decision No. 20-M-005/2019: In the Matter of the Proposed Acquisition by GlaxoSmithKline Consumer Healthcare Holdings Ltd. of Pfizer Inc.’s Consumer Healthcare Business

Commission Decision No. 20-M-005/2019:
In the Matter of the Proposed Acquisition by GlaxoSmithKline Consumer Healthcare Holdings Ltd. of Pfizer Inc.’s Consumer Healthcare Business

ABSTRACT

The transaction involves the proposed acquisition by GlaxoSmithKline Consumer Health Holdings Ltd. (“GSK CH”) of Pfizer Inc.’s (“Pfizer”) Consumer Healthcare business (“Pfizer CH”).

GSK CH, the acquiring entity, is an indirect subsidiary of GSK Plc., the United Kingdom-based multinational pharmaceutical company.

Pfizer CH, the acquired business, is a unit under Pfizer Inc., the US-based multinational corporation under its essential health business segment.

In the Philippines, the proposed transaction will be a pure acquisition of assets, including inventories, stock-in-transit, equipment, contracts, intellectual property, and goodwill, among others.

GSK, the acquiring ultimate parent entity, will issue to Pfizer non-controlling shares that will represent 32 % ownership interest in GSK Consumer Healthcare. Post-transaction, GSK will have 68% ownership and control over GSK CH.

GSK develops, manufactures, and markets a broad range of prescription, vaccine, and consumer healthcare products. GSK is present in the Philippines through Duncan Pharmaceuticals Philippines, Inc. and GlaxoSmithKline Philippines, Inc., both handling its prescription and vaccine products. They are also present in Duncan Consumer Healthcare Philippines, Inc., and GlaxoSmithKline Consumer Healthcare Philippines, Inc. which conduct its consumer healthcare business. SmithKline Beecham Research Limited is dedicated to both prescription and consumer healthcare activities.

Pfizer CH develops, manufactures, and markets non-prescription medicines, vitamins, and nutritional products in five areas: pain management, gastrointestinal health, respiratory, dietary supplements, and personal care. It also markets prescription products that have become over-the-counter.

1676957391_Commission-Decision-No.-20-M-005-2019_GSKPfizer_27-June-2019.pdf

Back